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Abstract: The discovery of the tumor-inhibitory properties of asparaginase (ASNase) began 
in the early 1950s with the observation that guinea pig serum-treated lymphoma-bearing mice 
underwent rapid and often complete regression. About 4000 cases of acute lymphoblastic 
leukemia (ALL) are diagnosed very year in the US and many more through out the world. The 
majority of these cases are in children and young adults, making ALL the most common form 
of malignancy in these age groups. The treatment protocols of ALL are complex and use 6–12 
drugs. Consequently, the improvement in the protocol design has improved significantly the 
success rate for long-term event-free survival in the past 20–30 years, which is now approximately 
75% for patients afflicted with the higher risk ALL features and just above this percentage for 
patients with standard or good features. Despite this success, approximately 15% of patients die 
from ALL, making leukemic relapse the most common cause of treatment failure in pediatric 
oncology. ASNases have been the cornerstone of ALL therapies since the late 1970s. Native or 
pegylated L-asparaginase (ASNase or PEG-ASNase) are highly specific for the deamination 
of L-asparagine (Asn) to aspartic acid and ammonia. Depletion of Asn leads to a nutritional 
deprivation and inhibition of protein biosynthesis, resulting in apoptosis in T-lymphoblastic 
leukemias, which require Asn from external sources. The reactions of the host exposed to 
repeated ASNase treatments as well as the up-regulation of the mammalian enzymes to overcome 
the ASN-depletion toxic condition are of significant importance and may make us relearn the 
lessons on this important antileukemic drug.
Keywords: acute lymphoblastic leukemia, asparaginase, enzymatic activity, pegylation, 
antibodies, asparagine, glutamine, pharmacokinetics, pharmacodynamics
Introduction
The aims of this article are to: 
1)  Review the mechanism of action of this class of protein inhibitor drugs, 
asparaginases (ASNase) as anti-leukemia drugs, 
2)  Review the clinical results and current use of ASNase from the published 
literature, 
3)  Present the population pharmacokinetic and pharmacodynamic studies on 
ASNase, 
4)  Present a pharmacological model for ASNase efficacy, 
5)  Review the principles of cellular and host resistance to ASNase, and 
6)  Inform the clinical oncologist on the latest of the pharmacology literature of ASNase 
formulations in newly diagnosed and relapsed acute lymphoblastic leukemia (ALL) 
patients. 
In these efforts, we admit that there are many limitations and unanswered questions, 
especially in the comparisons of the various ASNase formulations available around 
the world.
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History of L-asparaginase 
Despite the successful treatment of pediatric acute 
lymphoblastic leukemia (ALL) in recent years, 10%–25% 
of the ALL patients relapse early, quite a few while on 
maintenance therapy (30 months from induction). Then, 
their long-term outcome becomes problematic and uncertain. 
Pharmacological attempts to improve the treatment of 
relapsed patients have not been very successful, probably 
because of multiple genomic problems and acquired drug 
resistance, which can be manifested either as leukemia blast 
or host resistance. 
Among the drugs used as the cornerstone of combination 
protocols in the treatment of leukemias are the bacterial 
enzyme L-asparaginase (ASNase). The first discovery of 
the tumor-inhibitory properties of ASNase was 50 years 
ago, with the observation that guinea-pig serum treated 
lymphoma-bearing mice (particularly 6C3HED) underwent 
rapid and often complete regression (Kidd 1953). In the 
1960s, and continuing research in this field, Broome reported 
that ASNase activity in guinea-pig serum was responsible 
for the anti-lymphoma effects (Broome 1961, 1963). 
Inhibition of incorporation of L-asparagine (Asn), which 
caused alterations in protein and nucleic acid metabolism of 
the 6C3HED lymphoma cells by the guinea pig containing 
ASNase, was found to be responsible for the tumor growth 
inhibition (Sobin and Kidd 1966a, 1966b). The final proof 
that ASNase was the tumor-inhibitory agent of guinea pig 
serum was furnished by other investigators who isolated the 
enzyme to homogeneity as judged by immunoelectrophoresis 
and demonstrated that it was strongly inhibitory to lymphoma 
tumors (Yellin and Wriston 1966). Moreover, Mashburn 
and Wriston and others, found that Escherichia coli yielded 
preparations that inhibited tumors, but other bacterial 
ASNases were either less active or completely inactive 
(Mashbur and Wriston 1964; Broome 1965). Subsequently, 
the native E. coli ASNase was then developed as a drug for 
use in patients.
Biochemistry and mechanism of 
action of ASNase
Enzymes are the ideal catalysts for a given substrate, much 
more efficient and specific in their reaction characteristics 
than any man-made catalyst. However, when enzymes are 
used as drugs they have unique disadvantages, such bacterial 
protein purity and limited pharmacokinetic (PK) distribution 
in a mammalian system (mostly in the central compartment of 
the plasma volume), and they are often immunogenic to the 
host. These bacterial proteins must be purified extensively to 
eliminate toxic reactions and to minimize immune reactions, 
and they have limited biodistribution and rapid elimination 
from circulation (Capizzi and Holcenberg 1993). Despite 
these problems, native E. coli and Erwinia ASNase have 
made major contributions in the treatment outcome of ALL 
patients (Ertel et al 1979).
E. coli was shown to possess two enzymes, one expressed 
constitutively  (EC1, Km = 5 mM) and another induced 
by anaerobiosis (EC2, Km 12.5 μM); only the latter was 
tumor inhibiting (Schwartz et al 1966). L-asparaginase 
(L-asparagine amidohydrolase, EC3.5.1.1) is an enzyme, 
which catalyzes the hydrolysis of L-asparagine into L-
asparatic acid and ammonia (Figure 1). Tumor-inhibitory 
enzymes have been isolated from a number of other bacteria 
(such as Erwinia carotovora or Erwinia chrysanthemi), 
notably because of their use in the clinic (Wade et al 1968). 
Despite the low Km of EC2 it was found early on that it was 
necessary for the enzyme to persist sufficiently long in the 
circulation of the recipient animal for effective anti-tumor 
action. Consequently, multiple doses of native ASNase are 
administered in a time- and dose-dependent manner. Highly 
purified E. coli ASNase (EC2) became available to the 
pharmaceutical industry, and although striking remissions 
were reported in many of these patients with ALL who 
received the enzyme-drug, these remissions proved to be 
relatively short-lived with a median of 122 days of survival 
(Sobin and Kidd 1965; Oettgen et al 1967; Broome 1981). 
At about that time there was a clear understanding that 
ASNase was attacking neoplastic cells on the nutritional 
requirement caused by the lack of Asn. Then, the idea was 
Figure 1  Asparaginase deaminates both asparagine and glutamine.international Journal of Nanomedicine 2006:1(3) 243
Asparaginase for acute lymphoblastic leukemia
introduced of combining this agent with the newly discovered 
cytosine arabinoside (ara-C) and 6-mercaptopurine (6-MP) 
or thioguanine (6-TG) and daunomycin with vinca alkaloids 
to achieve 50-day cures in mice (Broome 1981; Burchenal 
and Karnofsky 1970). General nutritional deprivation, or 
Asn depletion, after ASNase treatment led to significant 
changes in the absolute pool sizes, especially of ATP, UTP, 
and CTP. Fluctuations were found depending on the elapsed 
time after the nutritional perturbations occurred. Depletion of 
the growth medium by 1 hour of guinea pig ASNase action, 
led to considerable inhibition of the conversion of exogenous 
uridine to CTP by the cells. A series of experiments indicated 
that in 6C3HED lymphoma cells, the uridine nucleotide 
pool, which provided the immediate precursors to RNA, 
behaves as a small compartment in rapid equilibrium with 
exogenously supplied nucleosides (Goody and Ellem 1975). 
Glutaminase-asparaginase from Pseudomonas 7A appears 
to have four subunits with a molecular weight of 36 kDa 
+/– 0.5 kDa by sedimentation equilibrium and 34 kDa by 
amino acid analysis. Analytic sedimentation equilibrium of 
the native enzyme showed a molecular weight of 140 kDa 
+/– 3.3 kDa with no signs of association or dissociation, 
or polymerization (Holcenberg and Teller 1976; Chabner 
and Loo 1996). Similar molecular weight is determined for 
E. coli ASNase (134 kDa), which maintains a significant 
glutaminase activity.
More on the mechanism of action 
of ASNase
As stated earlier, ASNase owes its antileukemic effect to the 
rapid and almost complete conversion of circulating Asn 
concentrations to aspartic acid and ammonia. Although Asn 
is not an essential amino acid, the thymus, and T-cell types of 
leukemia that lack this amino acid lead these cells to depend 
on extracellular sources of Asn for their protein synthesis. The 
serum contains a steady-state level of approximately 50 μM 
Asn. This amount of amino acid is derived from ingested 
nutrients and from de novo biosynthesis in the liver through 
the catalysis of aspartic acid and ammonia (from glutamine, 
Gln) by the mammalian enzyme asparagine synthetase (AS) 
(Avramis et al 2002; Panosyan et al 2004). One of the forms 
of drug resistance to this class of antileukemic agents is the 
upregulation of AS in the liver as well as in the leukemia 
cells, the net result of which is sufficient levels of Asn in 
circulation for protein synthesis. Elevated serum Asn levels 
are correlated with higher rates of events in children with 
relapsed ALL (Gaynon 2005; Jarrar et al 2006).
The side-effects of chemotherapy are many. However, 
the greatest shortcoming of the ALL treatment is its lack of 
efficacy in all patients. However, even in the higher risk ALL 
patients, of the patients who relapsed within 12 months of 
the completion of their primary therapy, about 75% achieved 
second remission by switching to the use of pegylated 
(PEG)-ASNase (Gaynon 2005; Jarrar et al 2006). This is 
in accord with the previously published studies in relapsed 
ALL patients where weekly PEG-ASNase was successful in 
re-inducing patients above 90% if they maintained elevated 
trough serum ASNase enzymatic activity levels (Abshire et 
al 2000; Hawkins et al 2004). Therefore, in Ab(–) patients, 
PEG-ASNase may still provide an advantage in inducing 
second complete responses (CRs). Conversely, delayed 
depletion of Asn and Gln for any biochemical or dosing 
reason, can cause the rebounding of these amino acids and 
the survival of the, now moderately or robustly, drug-resistant 
leukemia blasts.
The proof of principle of the usefulness of native ASNase 
was provided in 1979 when Ertel at al (1979) reported the 
first major study treating relapsed ALL with single agent 
E. coli ASNase (Figure 2). This study demonstrated clearly 
the unique ability of the drug used as a monotherapy to 
re-induce complete responses in relapsed ALL patients in 
a dose-response manner. The dose escalation of the drug 
demonstrated that 6000 IU/m
2 was the therapeutic dose to 
achieve approximately 60% re-induction complete remission 
without severe toxicity (Ertel et al 1979). The major limitation 
to the use of ASNase was the clinical hypersensitivity, which 
developed in 3% to 78% of patients treated with the native 
forms of the enzyme (Khan and Hill 1971). This important 
issue is discussed further later in this review.
Today, two products, native E. coli ASNase (ELSPAR
®, 
Merck, Inc.) and PEG-ASNase (ONCASPAR
®, Enzon 
Pharmaceuticals) are widely used against ALL in the USA. 
Figure 2  Dose-response of native asparaginase (ASNase) inducing second 
complete response (Cr) rates in pediatric acute lymphoblastic leukemia. 
Derived from data of ertel et al (1979).
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In Europe and Asia, the Kyowa-Hakko native ASNase 
formulations are available under different brand names, such 
as Crasnitin
TM and Medac
TM. All these ASNase are bacterial 
proteins, which act by deaminating the amino acids Asn and 
Gln (Holcenberg and Teller 1976; Capizzi and Holcenberg 
1993; Avramis et al 2002; Panosyan et al 2004). T-leukemia 
blasts are dependent on serum Asn for their protein synthesis; 
however, all lymphoblastic cells appear to be affected 
by ASNase. E. chrysanthemi ASNase (Erwinase) is also 
available for patients with clinical allergy to E. coli product. 
As stated earlier, all ASNases, being of bacterial origin, often 
induce a host response with the production of anti-ASNase 
antibodies. These antibodies eventually neutralize ASNase 
and this will be discussed later in the review. 
Native and PEG-ASNase: 
Pharmacokinetics and 
pharmacodynamics (PK–PD)  
in the host
As stated earlier, ASNase has been used very effectively for 
many years to treat ALL and other lymphoid malignancies. 
Leukemia cells lacking the mammalian AS enzyme depend 
on exogenous sources of Asn for protein synthesis and 
survival. Theoretically, the deamination of serum Asn and 
or Gln selectively kills leukemia cells, leaving normal cells, 
which have the ability to synthesize Asn intracellularly, 
unaffected. Many factors influence the antileukemic activity 
of ASNases. Among these are: the biochemical factors of 
the rate of hydrolysis, and the Km of the enzyme for Asn or 
Gln (Holcenberg and Teller 1976; Panoysan et al 2004); the 
pharmacological factor of serum clearance of the enzyme-
drug and the development of tumor cell resistance to ASNase; 
and the host immunological effects of anti-ASNase antibody 
formation, and augmented Asn “input” from the de novo 
biosynthesis of Asn by the liver and/or the contributions from 
nutrient intake (Capizzi and Holcenberg 1993; Panosyan et 
al 2002).
In the US, three ASNase formulations are available:  native 
E. coli ASNase (ELSPAR), its pegylated form ONCASPAR 
(monomethoxypolyethylene glycol –L-asparaginase, PEG-
ASNase), and Erwinia ASNase from E. chrysanthemi, which 
previously was available for patients with clinical allergic 
reactions to the other two formulations, and is now (summer 
2006) available again in the US (marketed by OPi, Lyon, 
France). Native E. coli ASNase has been used in higher 
doses, such as 10 000 or 25 000 IU/m
2 x 30 weekly doses 
(Capizzi 1993; Silverman et al 2001). Clearly, the three 
formulations have different half-lives of elimination after i.m. 
administration (Table 1) (Asselin et al 1993). In addition, the 
rates of anti-ASNase antibody formation vary significantly 
(Kurtzberg et al 1993; Woo et al 1998, 2000; Albertsen et al 
2001, 2002; Avramis et al 2002; Klug-Albertsen et al 2002; 
Panosyan et al 2004).
Asparaginase pharmacokinetic 
studies in standard risk ALL 
patients – CCG-1962
For this study, 117 children with standard-risk ALL were 
given randomized assignments to receive native or PEG-
ASNase as part of induction and 2 delayed intensification 
phases (Avramis et al 2002). Patients treated with PEG-
ASNase had more rapid clearance of lymphoblasts from day 
7 and day 14 bone marrow aspirates and more prolonged 
ASNase activity than those treated with native Asparaginase. 
In the first delayed intensification phase, 26% of native 
ASNase patients had high-titer antibodies, whereas 2% of 
PEG-ASNase patients had those levels. High-titer antibodies 
were associated with low ASNase activity in the native arm, 
but not in the PEG-ASNase arm. Adverse events, infections, 
and hospitalization were similar between arms. Event-free 
survival at 3 years was 82% (Avramis et al 2002). However, 
a recent follow up demonstrated statistical trend of difference 
in the Kaplan-Meier survival curves in favor of the PEG-
ASNase arm: 7/59 vs 11/59 relapses, which most likely 
is the sum of the effects of the mentioned advantages of 
Table 1  Asparaginases (ASNase) and their half-lives
Product  Source  T1/2 (days of depletion)  T1/2: CCG 1961, CCG 1962 
    (Asselin et al 1993)  (Avramis et al 2002)
E. coli native   Merck & Co, inc.  1.28 days  1.1 days 
ASNase    (14–23 days)  (CCG 1962)
PeG-ASNase  enzon Pharmaceuticals  5.73 days  6.0 days
(ONCOSPAr
®)    (26–32 days)  (CCG 1962)
erwinase  Speywood Pharmaceuticals, inc.  0.65 days  18.5 hours
Native ASNase    (7–15 days)  (CCG 1961)international Journal of Nanomedicine 2006:1(3) 245
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PEG-ASNase over the native enzyme (Avramis et al 2002). 
Further analyses demonstrated also that patients with higher 
than >1 μM of cerebrospinal fluid (CSF) Asn levels during the 
ASNase treatment were more likely to have isolated central 
nervous system  relapse later. It is imperative to emphasize 
that these low concentrations of Asn in CSF and serum 
specimens first reported in these studies in some patients 
have now been reproduced in other clinical studies (Appel 
et al 2003).
Non-linear mixed effects model 
population pharmacodynamic 
models
A population pharmacodynamic model (PPD) using the 
non-linear mixed effects model (NONMEM) program was 
developed that closely fits the measured enzyme activity 
and Asn concentrations. A population model for the one-
compartment open model using the NONMEM computer 
program was designed as described (Avramis et al 2002). 
The Michaelis-Menten (M-M) equation was programmed 
into a separate ADVAN/TRANS subroutine of this program, 
so that we could model serum ASNase enzymatic activity 
and its substrate Asn simultaneously. Serum PEG-ASNase 
activity and Asn values during induction were analyzed with 
a combined population PK–PD model, the M-M equation, 
and a NONMEM program. Pharmacokinetic parameters were 
fixed to estimates obtained in separate analysis of measured 
PEG-ASNase data and only pharmacodynamic parameters 
were estimated. Steady-state Asn concentration was assumed 
to be 50 μM. Pharmacodynamic modeling of native ASNase 
could not be done because of the repeated doses and 
infrequent sampling. However, classical population analyses 
were performed and were compared with the results from the 
NONMEM analyses for PEG-ASNase (Avramis et al 2002). 
The mean PEG-ASNase activity in serum peaked on day 
5 after the i.m. dose and averaged 1 IU/mL. The absorption 
from the i.m. site and elimination of PEG-ASNase from the 
serum were best described by single exponential functions. 
The mean T1/2 of absorption from the i.m. site was 1.7 
days and the elimination T1/2 of PEG-ASNase was 5.5 days 
(Table 1). A similar analysis showed a T1/2 of elimination 
to be 6 days (not statistically significant from the previous 
one). The one-compartment population analysis showed an 
apparent volume of distribution for the central compartment 
(Vdc) of 1.5 L/m
2. Clearance by non-compartmental and 
one-compartment models was estimated to 0.169 and 
0.18 L/m
2/day, respectively (not statistically different). The 
Vss estimated from the relationship of Vss = (dose*AUMC)/
(AUC)
2 was 1.86 L/m
2, calculated by the non-compartmental 
method based on statistical moment theory. The systemic 
Vd estimated from the one-compartmental analysis from 
the relationship of CL = Vd*Kel was 1.34 L/m
2. The average 
volume of distribution from different analyses was 1.5 L/m
2 
(Avramis et al 2002).
Elimination of native ASNase after the first induction 
dose was determined in one patient who had multiple samples 
drawn. A peak activity of 2IU/mL was seen 4 hours after i.m. 
administration and the T1/2,el was 1.1 days (Table 1). When the 
mean serum ASNase activity vs the days after the last ASNase 
dose were plotted for all the patients who received native 
ASNase they showed an elimination T1/2 for induction, delayed 
intensification #1 (DI 1), and delayed intensification #2 (DI 2) 
of 1.8, 1.5, and 1.5 days, respectively (Avramis et al 2002).
There was correlation between ASNase enzymatic 
activity and depletion of Asn or Gln in serum. This correlation 
was best described by a third-order regression – “sigmoid 
fit”. Under such pharmacodynamic conditions only a narrow 
range of enzymatic concentrations can achieve optimal 
substrate (Asn) deamination. The relationship between 
ASNase activity and percentage of Asn deamination was best 
fitted by a sigmoid curve. That curve indicated that serum 
Asn would be deaminated by 50% at an ASNase activity of 
0.05 IU/mL. A concentration of 0.7 IU/mL was correlated 
with much higher Asn deamination and a concentration of 
1.8 IU/mL of PEG-ASNase activity was estimated to cause 
a decrease of 96% in serum Asn. 
The population model estimated an apparent Km for 
asparagine deamination of 29 μM in these patients (in vivo), 
which is approximately three-fold higher than the literature 
value of 12 μM, a value, which has been determined under 
initial reaction rates and ideal biochemical conditions. There 
was no correlation between the volume of distribution, the 
half-lives of absorption or elimination of PEG-ASNase and 
surface area or age of patients. There was strong correlation 
between ASNase activity and glutamine concentrations in 
serum after administration of preparation. Gln concentrations 
were <100 μM when ASNase was >0.4 IU/mL with either 
form of ASNase. In CSF Asn depletion was not complete 
in all patients treated with either PEG-ASNase or native 
ASNase enzyme formulations. However, the population 
average on day 6 of induction was 0.9 log10 lower (average 
0.1 and 0.9 μM (n = 54; not statistically different)) in the PEG-
ASNase arm than the native arm. Intensive PEG-ASNase for 
newly diagnosed ALL should be tested further in a larger 
population (Avramis et al 2002). international Journal of Nanomedicine 2006:1(3) 246
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PD of PEG-ASNase in relapsed 
high risk ALL patients
Asn and Gln depletion after intensive weekly or biweekly 
administration of PEG-ASNase treatment has been 
correlated with the re-induction outcome in children with 
ALL in first bone marrow relapse (CCG-1941), despite the 
fact that ASNase enzymatic activity did not predict Asn 
depletion (Jarrar et al 2006).
 The hypothesis was that day 
14 Asn and Gln depleted levels would predict re-induction 
response (treatment outcome) in antibody-negative relapsed 
high risk ALL patients. In particular, we hypothesized that 
low day 14 serum Asn would predict favorable induction 
response. The results demonstrated that in patients with 
M1 marrow status at the end of induction, the mean day 14 
Asn level was 3.95 ± 2.5 μM; levels in M2 and M3 patients 
were 7.67 ± 7.67 μM and 14.83 ± 7.31 μM, respectively. 
The difference among response categories was statistically 
significant (p = 0.01). Sixteen of 19 patients with day 14 Asn 
levels <3 μM achieved M1 status compared with 5 of 11 with 
Asn levels >3 μM (p = 0.03). In other words, patients with 
day 14 Asn levels less than 3 μM and Gln levels less than 
127 μM achieved M1 marrow status, compared with patients 
with greater than 3 μM Asn or greater than 127 μM Gln who 
did not achieve CR (Jarrar et al 2006). A serum Asn level 
of 3 μM represents approximately 10% of the Km of this 
enzyme, a level at which the velocity of reaction (V) would 
be approximately 10% of Vmax as per the M-M equation. 
In separate studies where PEG-ASNase 2500 IU/m
2 
was administered weekly or biweekly, the trough serum 
enzymatic activity levels averaged 0.75–0.8 IU/mL at trough 
times, ie, on day 7, and accumulated to higher concentrations 
of 1.2–0.9 IU/mL on days 21 and 28 of induction or after 
the 3rd and 4th doses, respectively (Table 2) (Abshire et al 
2000; Hawkins et al 2004). Consequently, serum Asn was 
reduced significantly (p<0.002 for all comparisons) from 
day 0 to days 7, 14, 21, and 28 during induction. Serum 
levels of Asn were less than 3 μM in over 2/3 of the patients 
at each time point post-treatment both during induction 
and intensification. Similarly, Gln serum concentrations 
were below 100 μM in over 50% of the patients at these 
time points. Moreover, the CSF concentrations of Asn were 
progressively lower during induction, most patients having 
less than 1.5 μM. It is imperative to note that in other studies, 
low but detectable levels of CSF Asn were reported even 
after intravenous administration of PEG-ASNase (Appel 
et al 2003). Therefore, our findings of residual Asn in CSF 
of patients were consistent with subsequent clinical study 
findings. Furthermore, these findings are also consistent with 
isolated hepatic perfusion studies, which have suggested that 
the liver is capable of increasing Asn input to the circulation 
after ASNase treatments and in response to Asn deamination 
(Woods and Handschumaker 1973).
In addition, Asn may also be input to the circulation 
from the nutrients that are consumed by the host. Therefore, 
a possibility exists that an equilibrium of low Asn serum 
and, hence, CSF concentrations, can be achieved when the 
systemic input balances the rate of enzymatic depletion 
(Capizzi and Holcenberg 1993). This is especially true under 
lower serum ASNase enzymatic levels (trough times) during 
which M-M conditions the velocity of the Asn deamination 
reaction is much lower than the Vmax due to the low substrate 
concentrations. Conversely, the delayed administration of 
native ASNase from Friday to next Monday, given on the 
Mon-Wed-Fri treatment schedule, most likely intensifies this 
adverse pharmacodynamic effect. Thus, PEG-ASNase, not 
being subject to these time and dose variabilities, may be a 
more efficacious formulation. 
Treatment-related adverse 
effects: the anaphylactoid immune 
response to commonly used 
chemotherapy drugs
Despite the compromise of the immune system upon initiation 
of induction treatment of ALL, allergic or anaphylactoid 
reactions can occur after administration of many drugs, 
including native E. coli ASNase or PEG-ASNase. Other 
drugs associated with obvious clinical reactions are cis-
platin, cyclophosphamide, bleomycin, doxorubicin, cytosine 
arabinoside, and methotrexate (Weiss 1982). 
The most frequent and severe allergic reactions have been 
observed in patients after multiple doses of ASNase and, less 
frequently, PEG-ASNase. These obvious clinical reactions 
can occur after the second or third doses or even after many 
months post-induction therapy. The risk of the reaction 
is reduced when ASNase is given in combination with 
prednisone or dexamethasone and other immunosuppressive 
Table 2  weekly vs q 2 weekly pegylated asparaginase  
(PeG-ASNase) in first relapse (vPLD) 
PEG-ASNase  Number of  Asparaginase  2nd CR (%) 
dosing  patients  trough levels   
    in CR pts
q 2 weeks  63 
0.75 iU/mL
  50 (79%)
q weekly  63    61 (97%)
Derived from results of Abshire et al (2000)international Journal of Nanomedicine 2006:1(3) 247
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agents. Substitution of native ASNase with PEG-ASNase or 
E. carotovora ASNase circumvents recurrent anaphylactoid 
reactions once a reaction to native ASNase has been 
documented. However, the IgG antibodies against native 
ASNase can recognize the pegylated antigen and the injection 
of Erwinase can initiate its separate immune reaction and 
development of anti-Erwinase antibodies (Albertsen et al 
2001, 2002; Klug-Albertsen et al 2002).
Clinical manifestations of ASNase hypersensitivity 
reactions are:
anaphylaxis (rare)
allergic reactions
edema
serum sickness
broncospasm
urticarea and rash 
itching and swelling of extremities
erythema – local or generalized
other clinically related reactions
Other toxicities to ASNases include: 
organ toxicities
  pancreatitis and related hyperglycemia, glucosuria, 
ketoacidosis
liver dysfunction
cerebral dysfunction
decreased protein synthesis:
hypoalbuminemia
hypofibrinonemia
hypercoagulable state – coagulopathies
clotting factors
Immune response to ASNase 
antigen: cumulative dose exposure 
of an antigen (ASNase) and 
immune response relationships 
In classical immunization, the amount of the bacterial or viral 
proteins is known and a gradually increased dose exposure of 
the antigens(s) is re-inoculated on subsequent immunizations. 
In oncology, it is impossible to estimate the dose of ASNase 
antigen in mmol per kg of body weight of ALL patients, 
since neither ASNase formulation provides the relevant 
information of IU of mg or mmol of protein concentration 
on the supplied package insert. 
The immune reaction to the first dose of ASNase 
is extremely rare and occurs in patients with atopic 
predisposition. Atopy is mediated by genetic factors with the 
presence of specific human leukocyte antigen (HLA) alleles, 
environmental factors, eg, allergen sensitization, and defects 
in target organs, eg, skin, gastrointestinal mucosa, and oral 
epithelium. However, upon re-exposure of many doses of 
either native ASNase or PEG-ASNase the theoretical IgA → 
IgM → IgG is assumed to be taking place at 0.1 mmol/kg of 
body weight. Clinical allergic or anaphylactoid reaction may 
occur when the levels of circulating IgG antibodies against 
ASNase become elevated. The first exposure to ASNase most 
likely produces a primary response. Subsequent treatments 
will yield a secondary (or anamnestic) and tertiary immune 
responses. Obvious clinical reaction can then take place. 
When there is successful pre-conditioning of the host with 
prednisone, the depletion of helper T-cells and other immune 
cells is assumed; hence, there is unresponsiveness to the 
subsequent ASNase administrations. Upon discontinuation 
of the ASNase therapy, the circulating IgG antibodies decline 
to non-detectable levels. However, the memory B cells are 
assumed to exist in the host for life.
Moreover, there seems to be a relationship between the 
age of the patient and immune response. The infants and 
the younger patients are less likely to develop antibody 
positivity and obvious clinical reaction to ASNase therapy. 
In contrast, teenagers and adult patients are more likely to 
react to ASNase treatments. 
The IgE antibodies do not fix the antigenic compliment, 
yet mediate immediate (acute) and severe hypersensitivity 
reactions by causing the release of mediators from mast cells 
and basophils (histamine and leukotrienes), upon re-exposure 
to the antigen. In contrast, the IgG are the main antibodies 
responsible for the moderate to slight allergic reactions and 
the product of secondary immune response (humoral immune 
response). These antibodies fix onto the compliment and 
neutralize the antigen (toxin) or foreign protein. IgA and 
IgM are primary response antibodies in the progression of 
immune response to IgG or IgE antibodies, a process called 
affinity maturation. 
Antibodies to ASNase 
formulations: the CCG Standard 
Risk ALL experience
The primary endpoint of the CCG-1962 study was to find 
whether incidence of high-titer anti-ASNase antibodies in 
children treated with PEG-ASNase was decreased by at 
least 50% in DI 1 compared with those treated with native 
ASNase (Avramis et al 2002). A secondary endpoint was to 
show whether the same decrease occurred in DI 2. ASNase 
therapy is given frequently per clinical protocols. However, international Journal of Nanomedicine 2006:1(3) 248
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there were no serum specimens obtained during consolidation 
or interim maintenance 1 to clearly define the exact timing 
of the anti-ASNase antibody appearance. Therefore, the 
question of “when antibody first appeared” is important. 
We believe that this is not the subject of a review article to 
address, but may be a suitable subject for a prospective study. 
The mean + SEM antibody ratio in DI 1 was 1.9 + 0.8 (n = 47) 
for children treated with PEG-ASNase and 3.0 + 0.7 (n = 43) 
for those treated with native ASNase (p = 0.001 by Wilcoxon 
two-sample test). The respective mean + SEM ratios for 
PEG-ASNase and native ASNase were 1.3 + 0.2 (n = 41) and 
2.3 + 0.9 (n = 47) for induction (NS) and 2.1 + 0.8 (n = 45) and 
2.1 + 0.6 (n = 45) for DI 2 (NS). The difference in high-titer 
antibodies was especially evident in DI 1, in which 11 of 43 
children in the native ASNase arm had ratios >2.5, whereas 
1 of 47 in the PEG-ASNase arm had that level (p = 0.001, 
Wilcoxon test) (Avramis et al 2002). The differences were less 
apparent in DI 2 (p = 0.09, Wilcoxon test) and not significant 
during induction. Comparison of the maximum antibody ratio 
of each patient, irrespective of cycle, showed higher titers in 
the native ASNase patients (p=0.0009, Wilcoxon test). We 
anticipated that 50% of children treated with native ASNase 
would have antibody ratios of at least 2.5 at some time during 
their therapy. Only 26% of children in the native ASNase arm 
had ratios >2.5 but over 40% of them had ratios of >1.5. The 
antibody levels tended to decrease between days 7 and 28 
of each ASNase-containing phase and were lower in DI 2 
than DI 1 (Table 3) (Avramis et al 2002). In conclusion, the 
antibody formation along with the genetics of the leukemia 
blasts resulting in different immunoglobulin rearrangements 
may constitute a pharmacogenomic characteristic.
Novel approaches to test for cross-
reactivity of ASNase formulations
In the era of recombinant DNA gene product(s) expression 
into therapeutic drugs, for example, human adenosine 
deaminase (ADA), humanized anti-VEGF-A antibody, and 
many similar monoclonal antibodies against oncoproteins,   
the possibility that a novel ASNase formulation forms a 
known bacterium or from new ones is in the planning stage 
or about to become available for testing in patients. We and 
other investigators are testing or are about to test in current 
clinical trials in relapsed ALL patients monoclonal ASNase 
derived from recombinant DNA technologies, which are   
purer than anything we have available in our armamentarium. 
In the past decade, the ASNase extracted from E. carotovora 
(renamed: E. chrysanthemi) has been used clinically. The 
advantages of this ASNase formulation are that it possesses 
greater glutaminase activity (the ability to deaminate Gln) 
with a Km approximately one-half the concentration that 
native E. coli ASNase does, and that it lacks cross-reactivity 
(Capizzi and Holcenberg 1993). Conversely, PEG-ASNase 
antigen does not cross-react immediately with the antibody 
against native ASNase, but in time it will cross-react. 
Therefore, when obvious clinical allergic reactions are 
documented in patients who had been treated with native 
ASNase and then PEG-ASNase, these patients were treated 
successfully with Erwinia ASNase. Currently the formulation 
is available in Europe, but not in the US. 
Other ASNase with or without glutaminase activities 
have been tested in the past, specifically those proteins from 
Vibrio succinogenes (renamed Wolinella succinogenes), an 
anaerobic bacterium. Like native E. coli ASNase, this is 
Table 3  Anti-asparaginase (pegylated, PeG-ASNase; native ASNase) antibody presentation in various treatment phases and studies
  CCG-1962  CCG-1991  CCG-1961 
  (PEG vs native-ASNase)  (PEG-ASNase)  (native/PEG-ASNase)
% patients with anti-  end of induction  14%  60% (611/1001)
ASNase antibody  PeG 5%, native 15%    (Panosyan et al 2004)
  end of Di 1 (6 months)
  PeG 11%, native 41%
  end of Di 2 (10 months)
  PeG 18%, native 44%
rate of events  PeG 8/58    No allergy 3/57 (5%)
  Native 16/58    Allergy, changed to 
      erwinase 3/115 (2.5%)
  (Current data)    Silent, no change to  
      erwinase 13/81 (16%)international Journal of Nanomedicine 2006:1(3) 249
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a homotetrameric enzyme consisting of 330 residues and 
of similar molecular weight. The amino acid sequence is 
40%–50% identical to the sequences of related proteins from 
other bacterial sources, and all residues previously shown 
to be crucial for the catalytic action of these enzymes are 
identical (Lubkowski et al 1996). However, this antigen is not 
cross-reacting to Ab(+) sera from patients treated with native 
ASNase or PEG-ASNase. Therefore, there is a theoretically 
potential advantage in treating ALL patients optimally with 
Wolinella ASNase. Moreover, the ASNase isolated from 
Serratia marcescens has an apparent average molecular 
weight of 171 000–180 000 as determined by electrophoresis 
on polyacrylamide gels, with each subunit having a molecular 
weight of 31 500 +/– 1500. The Serratia enzyme could 
have five or six subunits of 32 000 Da, compared with four 
subunits of 32000Da in the native E. coli enzyme. The 
Serratia ASNase also appears to be a larger molecule than the 
enzyme from E. carotovora (Stern et al 1976). ASNase from 
Serratia marcescens was found to hydrolyze L-glutamine at 
5% of the rate of L-asparagine hydrolysis and that the two 
activities had parallel blood clearance rates in mice (Novak 
and Philips 1974). 
With these many and different ASNase formulations 
potentially available for human testing, one could envision 
creative ways to test their cross-reactivity between the 
Ab(+) sera from patients treated with native ASNase and/
or PEG-ASNase formulations. One could design a new 
protocol alternating ASNase formulations of appropriate or 
bioequivalent dosing before any evidence of host response 
is evident. This task could be accomplished only by an 
experienced pharmacologist after appropriate thought and 
justification and not to be left in the hands of the young but 
exuberant investigator. Hence, no haphazard processes should 
be attempted in implementing these suggestions. ASNase 
formulations are antigens to human hosts and need to be used 
wisely. Moreover, and in order to assess the cross-reactivity, 
Ab(+) sera from patients could (must) be incubated ex vivo, 
with various concentrations of these alternative and possibly 
useful ASNase formulations (antigens) in large numbers 
to determine statistically the true rate of cross-reactivity. 
Assuming that one has a potentially non-cross-reacting 
ASNase formulation, like Erwinia ASNase, one then must 
proceed with inoculations of animals, rabbits, or mice with 
either antigen, then cross-react with the alternative antigen 
and observe for immune reactions. An alternative to this 
experiment could be that the antigen-tolerating mice and 
assumed Ab(+) could be inoculated with murine leukemia 
cells and the alternative ASNase formulation could be tested, 
for instance, against their L1210 leukemia. The assessment 
of the results from these studies should then guide the 
investigators for further evaluation in patients.
Toxicity of ASNases
The toxic effects of ASNase are related primarily to immune 
reactions to this bacterial protein and to the effects of Asn 
depletion, and its subsequent inhibition of protein synthesis 
in major glands such as the liver and pancreas. The allergic 
reactions are the most prominent toxicities, and although 
grade 3 and 4 are lower than grade 1 and 2, they are primarily 
due to anti-ASNase Ab(+) in circulation. In the high risk ALL 
study (CCG-1961) clinical allergy and high titer Ab were 
very common with the augmented regimen on CCG-1961 
(Avramis et al 2002; Panosyan et al 2004).
Patients received 46 doses of native ASNase or 10 
doses of PEG-ASNase after induction, most with no steroid 
immunosuppressive coverage in consolidation and interim 
maintenance 1 (IM1) phases of treatment (Table 3). About 
one patient in three had clinical allergy symptoms compared 
with fewer than 5% in CCG-1962, where patients received 
ASNase only with steroid immunosuppression without 
alterations in the pharmacokinetic profile of the drug 
(Avramis et al 2002; Panosyan et al 2004). Clinical allergy 
was most common when ASNase was given without steroids. 
For this, we hypothesize that limiting ASNase therapy to 
the times of steroid immunosuppression will decrease the 
frequency of clinical allergy, prevent the appearance of high 
titer antibodies, achieve greater Asn and Gln depletion in 
serum, and improve outcome. Nevertheless, we still do not 
know the best way to administer these bacterial proteins to 
achieve optimal effect and to minimize allergic reactions. 
The paper by Panosyan et al (2004) provides some additional 
and important clues. Several laboratories have shown that 
treated patients can develop a silent allergy where circulating 
antibodies neutralize ASNase activity resulting in an 
ineffective contribution by the drug to the anti-leukemic 
pharmacodynamic effect, without causing obvious clinical 
allergic symptoms. When this occurs these patients receive a 
shorter duration of effective ASNase treatment. This suggests 
that monitoring for silent anti-ASNase antibodies or loss of 
ASNase activity could provide a better understanding of this 
class of anti-leukemic drugs and thereby improve outcome. 
Correlative factors in ALL 
treatment outcome
A statistical interim analysis was released 4 years after 
the opening of CCG-1961 study. According to this study’s international Journal of Nanomedicine 2006:1(3) 250
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protocol, 1200 pediatric patients received 9 doses of native 
E. coli ASNase during induction and then 2 doses of PEG-
ASNase during consolidation. Four or more specimens 
were obtained from the vast majority of patients per study 
protocol CCG-B951. Patients were selected randomly for 
the anti-ASNase antibody assays. Among these patients 410 
had 4 or more sera specimens assayed for antibody titer. The 
results were expressed as a ratio over negative control per 
ELISA assay. The data were transmitted to the statistician’s 
office at the CCG Statistical Center, who performed an 
interim analysis with treatment outcome. Among the 410 
patients, 280 had all clinical data available for evaluation 
of efficacy, clinical allergy, and outcome for 30 or more 
months. The remaining patients lacked clinical data or they 
had not completed 30(+) months from induction treatment. 
According to the interim analysis, the antibody and clinical 
event data (event free survival, EFS) showed that there were 
4 sub-sets of patients, the three proposed ones and a fourth 
consisting of patients with clinical allergy symptoms and 
Ab(–) sera (false negative reaction or reaction to other agents) 
(Panosyan et al 2004). The historical data from ALL studies 
in CCG show an 80% EFS in 5 years with very few relapses 
after this time. 
The results of this interim analysis demonstrated that 
the largest subset of patients (41%) developed anti-ASNase 
Ab(+) and had clinical allergy symptoms. We have shown in 
other studies that the Ab are inhibiting the ASNase enzymatic 
activity, thus allowing the serum Asn to rebound. The Ab(+) 
has an adverse effect on treatment outcomes which was 
statistically significant in the survival of these patients. This 
subset of patients received no effective ASNase therapy 
post-induction. Therefore, patients with anti-ASNase Ab(+) 
have a worse outcome than any other subset. Since the silent 
hypersensitivity subset is large (29% of evaluable patients), 
approximately representing the 25% of all high risk ALL 
patients who relapse in 5 years from diagnosis, the anti-
ASNase antibody could be a surrogate marker, which is 
responsible for the poor outcome in this disease. The interim 
analyses have shown that the anti-ASNase antibody has a 
predictive clinical value and that switching patients with 
Ab(+) from  native ASNase to Erwinase may benefit their 
outcome, as indicated by the reversal of the hazard ratio from 
3.22 to 0.6 (Panosyan et al 2004). Should the final analyses 
be as important as the interim ones, this model can then 
be used for alternating ASNase formulations for improved 
treatment outcome in ALL. Therefore, Ab(+) should be the 
primary surrogate marker for treatment outcome in future 
clinical trials. In Ab(–) patients the serum trough levels may 
be of significant importance, and perhaps more important, 
the examination of percentage deamination of Asn and Gln at 
trough times should be the guiding factor(s) for determining 
correlative outcome analyses.
How best to optimize these ASNase formulations in newly 
diagnosed ALL patients still remains a challenge. With the 
reduced or lack of support from the NIH-NCI for clinical 
studies in oncology patients with “old” but very useful drugs, 
the possibility that these evaluations will be performed in 
many hundreds of thousands of patients is nil. The more 
immediate the “need to know” of these PK parameters are 
in relapsed ALL patients, whose survival is at high risk, the 
less interest and hence, the lower the NCI funding support. 
Relapsed ALL patients are still treated with many of the same 
drugs they had been treated with as newly diagnosed patients, 
perhaps with more complex protocol design or increased 
doses or dose intensity. However, the results from such 
studies are few and therefore the knowledge for application 
to the general relapsed patient population is very slim. But 
the limited data, along with the latest results from targeted 
therapies in leukemias, may be the subject of future research 
on effectively targeting relapsed leukemias.
We still remain optimists that, somehow, there will be a 
time and place when these important scientific questions in 
newly diagnosed or relapsed ALL pediatric and adult patients 
will be answered and that much good shall be derived for the 
ALL patients of this world. Many lessons have been learned 
(Table 4), and many more to be learned in the near future.
Genetics of ALL leukemia blasts
Many genetic factors, such as chromosomal abnormalities   
and karyotypic changes, lead to HLA (major histocompati-
bility complex) polymorphisms. The notion of the existence 
of the leukemia stem cell (LSC) is novel and worrisome 
(Jamieson et al 2004). In addition, micro-environmental 
factors are influencing the pro-survival and growth of the 
LSC. Many other factors, like optimal drug dosing, age, 
gender, growth factors in circulation, immune system 
maturity, supportive care, and response to foreign antigens 
of the host may play important roles in the response to 
chemotherapy treatments. 
Translocations and other chromosomal aberrations are 
important in treatment outcome. Monosomies, trisomies, Bcr-
Abl, Flt-3, MLL-AF4, TEL-AML1, and many other oncogene 
expressions play important roles in the outcome of leukemias. 
However, the pattern of the Bcr-Abl and other translocations’ 
transcript levels is often variable; only a minority of patients 
with fluctuating or persistent levels of oncogene transcripts international Journal of Nanomedicine 2006:1(3) 251
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are evident at diagnosis or at the end of induction treatment, 
thus defining molecular relapse(s). Yet, as the surviving 
minimum residual disease (MRD) leukemia cells are 
“enriched” by these drug-refractory blast cells, the majority 
of these patients who responded initially to targeted therapy 
(eg, imatinib mesylate in Ph(+) chromosome leukemias) are 
likely to be subject to disease progression due to imatinib-
resistant Ph(+) ALL blasts (McLean et al 2005).
Furthermore, patients whose leukemia blasts exhibit 
significant differences in the metabolism and interactions of 
purine and pyrimidine nucleoside anabolite drugs, such as 
fludarabine, cladribine, and cytosine arabinoside (ara-C), may 
have differences in the initial and subsequent dose responses 
(Avramis et al 1989; Robak 2005). Given the complexity of 
the immune response and abnormalities in host immunity 
induced by different cancer cells and their treatments, it is not 
surprising that early attempts with clinical immunotherapy 
have not been successful. This, along with the notion that 
tumor mutations continue to occur with the progression 
of the malignancy, make neoplasms difficult to treat with 
immune-based modalities or more intensified treatments and 
bone marrow transplantation. Therefore, reasons for ALL 
relapse are many and complex. Yet survival of patients in 
third remission is less than 10%; hence, novel agents must 
be integrated into multi-agent combination regimens, which 
should be applied as early in relapse as possible. Lastly, since 
most new agents fail investigational clinical trials despite 
“compelling” pre-clinical data and enthusiastic investigator’s 
efforts, the progression from the bench to bedside should 
require intermediate steps and careful considerations 
(Gaynon 2005). 
Relapse ALL: an unconventional 
future challenge for leukemia 
patients
Despite the great progress that has been made in the treatment 
of ALL patients with intensified therapies and the use of 
optimal ASNase formulations, unfortunately a certain 
percentage of ALL patients relapse. The present and future 
challenge in ALL is the relapsed patient population. 
Relapse ALL is identified by the reappearance of 
leukemia blasts after achieving different periods of clinical 
remission. Considerable advances have been made in the 
past decades in the treatment of front-line ALL, with long-
term cure rates approaching 85%. Relapses in ALL are 
unfortunate events in patients with resistant, refractory ALL 
(Gaynon 2005). According to Pui and coworkers at St Jude’s 
Hospital (Memphis TN, USA), the risk of leukemia relapse 
was 10.0% ± 1.1% at 5 years and 11.4% ± 1.2% at 10 years 
after diagnosis of treated ALL between 1984 and 1999 (Pui 
et al 2005). Moreover, the outcome of ALL is very grim 
after relapse, with chances of survival of only 10%–40% 
after second clinical remission and <10% after third and 
subsequent relapses (Gaynon 2005), although second clinical 
remissions have been achieved in as much as 85% of the 
relapsed ALL cases. 
Relapse ALL may be stratified into three risk patient 
groups: low, intermediate, and high-risk. Combined late 
bone marrow relapse or late isolated bone marrow relapse 
constitute the low risk group of ALL relapse; isolated 
extramedullary relapse or the early combined bone marrow 
relapse constitute the intermediate risk group; and the 
early isolated bone marrow relapse, T-cell relapse, or the 
ALL relapse with Bcr-Abl fusion constitute the high risk 
relapse. 
Different sites may be involved in relapse ALL: bone 
marrow with >25% blasts any time after induction without 
extramedullary involvement, extramedullary relapse (CNS, 
testicular, or other sites like the orbits) with <5% blasts in 
the bone marrow, or combined relapse with >5% blasts in 
bone marrow with extramedulary disease. The timing of the 
relapse has been expressed differently in different protocols. 
The Children’s Oncology Group (COG) ALL investigators 
differentiate early bone marrow relapse as ALL relapse 
occurring within 3 years of the first clinical remission of 
Table 4  Summary of asparaginase (pegylated, PeG, or native 
ASNase) dosing and pharmacokinetic–pharmacodynamic 
parameters
a)  Native ASNase dose 6000 iU/m
2 q 48 hour x 2 or 3 weeks
    PeG-ASNase 2500 iU/m
2 q 4 weeks in front-line, or q 2 weeks or  
q weekly in relapsed ALL patients
    Antibody presentation: Native ASNase: 44% in Sr ALL pediatric 
patients
  PeG-ASNase: 18% in Sr ALL pediatric patients
b)    ASNase 0.75 iU/ml serum concentration highly correlates with Cr2 
in relapsed patients (Abshire et al 2000)
    ASNase >0.7 iU/mL trough levels → Optimal deamination of Asn and 
Gln (Hawkins et al 2004)
c)    ASNase 0.7 iU/mL serum concentration deaminates >90% of Asn and 
Gln (Panosyan et al 2004)
d)    90% deamination or better of Asn (<3µM in serum) is required to 
achieve second Cr in CCG-1941 study (Jarrar et al 2006)
    An approximate ASNase activity of 0.7 iU/mL is required to kill 90% 
of T cells in vitro
Abbreviations: ALL, acute lymphoblastic leukemia; Asn, asparagines; Cr, complete 
response; Gln, glutamine.international Journal of Nanomedicine 2006:1(3) 252
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induction therapy, whereas late bone marrow relapse is 
relapse occurring after 3 years of the first clinical remission. 
It also differentiates early extramedullary relapse ALL as one 
occurring within 18 months of diagnosis of ALL and late 
extramedullary relapse as one occurring after 18 months of 
ALL diagnosis. 
Relapse ALL may occur after standard risk, high risk, or 
very high risk ALL, after pre-B cell, B-cell, T-cell, Ph+ ALL, 
infant ALL, or after t(4;11), t(1;19), or t(8;14). In treatment of 
ALL as many as 8–12 drugs are administered. Therefore, in 
patients in relapse of this disease, treatment failure by native 
ASNase should be substituted by the intensive use of PEG-
ASNase (Abshire et al 2000; Hawkins et al 2004; Jarrar et al 
2006).Treatment failure without obtaining clinical remission 
leads to persistent disease in contrast to relapse ALL, in 
which there are varying periods of clinical remission before 
the relapse. Naturally, treatment failure may be due to drug 
resistance to many other drugs and one should not expect 
the contribution of one drug formulation to answer all the 
complicated questions in ALL treatment. Relapse ALL usually 
retains its original immunophenotype. Different mechanisms 
for relapse ALL have been postulated, for example: the 
presence of defective death pathways for apoptosis or 
necrosis; use of inappropriate drug(s) in inappropriate 
doses and/or in appropriate sequences; the presence of 
inhibitors of drugs or antibodies to the drugs used; presence 
of genetic deviations of specific drug metabolism pathways 
(thiopurine methyltransferase [TPMT], over expression of 
genes associated with vincristine, prednisone, asparaginase, 
daunorubicin or other drugs) leading to drug resistance or 
refractory disease; and the presence of refractory leukemia 
cells (leukemia stem cells). Different prognostic factors may 
be attributed to the outcome in relapse ALL. The duration 
of the first or subsequent clinical remission is an important 
prognostic factor. The shorter the duration of the clinical 
remission the worse the outcome of relapse ALL. Certain 
immunophenotypes of relapse ALL have worse outcomes, 
such as T-cell relapse, Ph+ relapse, infant ALL relapse 
with MLL 11q23 rearrangement, and relapse with severe 
hypodiploidy or with translocations t(8;14), t(4:11), t(1;19). 
Suboptimal treatment in terms of sequential combination 
multi-drug chemotherapeutic agents, dosage, duration of the 
therapy, and poor patient compliance influence the outcome 
as well as the frequency of subsequent relapse. 
In late isolated bone marrow relapse the tumor burden 
(blast count at relapse) influences the future outcome. Isolated 
bone marrow relapse has a worse outcome than combined 
or isolated extramedullary relapse. The presence of multiple 
or severe co-morbidities at relapse as well as the nutritional 
status of the patient in terms of obesity or under-nutrition 
leads to impaired drug levels and rebound or increased drug 
toxicities. The presence of M3 bone marrow status (>25% 
lymphoblasts) at any point after achieving clinical remission 
on day 29 induction of newly diagnosed ALL denotes bone 
marrow relapse. Bone marrow relapse is the principal form 
of treatment failure in ALL. 
The time of the bone marrow relapse determines the 
outcome of the treatment: early bone marrow relapse has 
worse outcomes than late bone marrow relapse. Isolated bone 
marrow relapse, initial high white blood cell count in late 
isolated bone marrow relapse, bone marrow relapse with T-
cell or BCR-ABL fusion as well as a short duration of the first 
or subsequent clinical remissions lead to poorer outcome in 
bone marrow relapse ALL, which is also affected by the nature 
and dosing of the chemotherapy. Isolated extramedullary 
relapse ALL occurs, with extramedullary disease containing 
>5% blasts in the bone marrow. Extramedullary disease with 
>5% blasts in the bone marrow constitutes combined relapse. 
Extramedullary relapse commonly occurs in the CNS or 
the testes but may occur at other sites like the orbits. The 
COG differentiates early extramedullary relapse ALL as 
one occurring within 18 months of diagnosis of ALL while 
late extramedullary relapse as one occurring after 18 months 
of ALL. Approximately 10% of the patients with ALL, 
especially those with hyperleucocytosis or T-cell leukemia, 
suffer from CNS relapse. The CSF values show CNS-3 
disease with >5% white blood cells and unequivocal number 
of blasts and/or signs of CNS disease (cranial nerve palsy, 
brain or eye involvement, or hypothalamic syndrome). The 
incidence of testicular relapse has gradually decreased from 
5% to 17% in the early 1980s to about 3.4% in the late 1990s. 
Recently, approximately 2% of the male patients with bulky 
disease were reported to suffer from testicular relapse of 
ALL. Testicular relapse is manifested by unilateral or bilateral 
testicular enlargement and diagnosed by wedge biopsy, taking 
into account the involvement of the contralateral testis. 
An EFS of 66.7% at 10 years was found with aggressive 
chemotherapy without irradiation (Shama et al 2005). 
Relapses in leukemia are and will remain a major 
challenge for oncologists in the 21st century. Despite 
aggressive chemotherapy and hematopoietic stem cell 
transplants (HSCT) most children with relapse die and the 
chance of survival is only 10%–40%. The ideal treatment 
to increase the survival of patients with relapse ALL is still 
lacking but the effort is still ongoing. The present treatment for 
relapse ALL consists of multi-agent systemic chemotherapy international Journal of Nanomedicine 2006:1(3) 253
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with CNS-directed therapy and HSCT for some patients. 
EFS and overall survival are best for late bone marrow 
and combined bone marrow relapse ALL. With improving 
treatment there is an ongoing tendency for increasing CNS 
relapses. The current approach in COG is to use different 
treatment protocols, eg, AALL01P2 for bone marrow relapse 
patients and patients with combined relapse ALL, and 
AALL02P2 for the late isolated extramedullary relapse ALL 
with CR1>18 months, and ADVL04P2 trial with multi-agent 
chemotherapy supplemented by the anti-CD22 monoclonal 
antibody epratuzumab. Future considerations in relapse ALL 
should take into account the prevention of relapse of ALL by 
appropriate categorization and aggressive therapy for newly 
diagnosed ALL with a tendency to relapse. Use of gene-
expression profiles and micro-array technology to categorize 
as well as monitor the dynamics of high risk for relapse ALL 
treatment, early introduction of courses of targeted multiple 
monoclonal antibody therapy (especially against leukemia 
stem cells) for ALL with increased risk of relapse, as well as 
combating drug resistance and refractoriness by monitoring 
treatment to maintain appropriate drug levels for maximum 
leukemia cell kill may prove fruitful in the future. Identifying 
ALL types that escape the above measures and looking into 
newer novel therapies is still another challenge. 
Finally, the pharmacodynamic question on the use 
of ASNase in relapsed ALL patients is whether more 
intensive dosing (shorter time interval) and/or continuous 
or uninterrupted ASNase dosing is providing a tolerable 
regimen with optimal outcomes. Certain PK–PD simulations 
on these issues have been performed, suggesting that the more 
intensive PD effect that is derived from more frequent ASNase 
dosing may be beneficial to treating optimally ALL patients 
(Avramis et al 2005). Our patients are awaiting our action.
Conclusions
ASNase is a tetramer protein that deaminates Asn and Gln. 
ASNase inhibits protein synthesis in T-cells. The average IC50 
concentration of PEG-ASNase is 0.4 IU/mL. Gln deamina-
tion is necessary for optimal Asn deamination and, therefore, 
leukemia blast kill. PK–PD analyses show that PEG-ASNase 
provides a better day 7/14 bone marrow response. ASNase 
activity of 0.4–0.7 IU/mL provides greater than 90%   
depletion in vivo (with hepatic asparagine biosynthesis) 
(CCG-1961 and CCG-1962). 
Better Asn and Gln deamination are associated with 
improved EFS. High titer anti-ASNase antibody is found 
in some children with no clinical allergy (silent hypersens-
itivity). IgG antibody neutralizes ASNase activity. Anti-
ASNase antibody production leads to inferior treatment 
outcome in patients with ALL. The purpose of intensive 
therapy in ALL is also the prevention of immunization to 
ASNase. The longer activity and less immunogencity with 
PEG-ASNase may increase EFS and the quality of life. 
Neutralizing antibody development against native ASNase 
has cross-reactivity with PEG-ASNase but not with Erwinia 
ASNase. The dosing of all formulations should be monitored 
for activity. The early use of PEG-ASNase may require lower 
dosing and may be more cost effective. A more intensive 
ASNase dosing may be required to provide high trough levels 
of 0.4–0.7 IU/mL in relapsed ALL patients.
ASNase therapy for the treatment of newly diagnosed 
and recurrent–refractory leukemias is an important milestone 
in the efforts to achieve high EFS, overall survival, with 
little toxicities and events in patients with these diseases. 
Maintaining optimal ASNase enzymatic activity at 0.4–
0.7 IU/mL, low anti-ASNase antibodies in these patients, 
and optimal depletion of Asn and Gln play a vital role in 
achieving these goals. Hence, appropriate monitoring of 
these parameters during therapy is of the utmost importance. 
Prevention of relapses in leukemias could be further ensured 
with intensive ASNase dosing (weekly or biweekly) and 
appropriate monitoring of these parameters during treatment 
of newly diagnosed leukemias. Future studies should 
examine additional aspects that would promote effective 
ASNase therapy, like the role of asparagine synthetase, 
gene expression profiles, and micro-array technology in 
order to categorize leukemia patients and search for inherent 
resistance or refractoriness to ASNase. 
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